{"title":"贝伐单抗可能克服转移性结直肠癌患者对伊立替康化疗的临床肿瘤耐药:病例报告","authors":"J. Zekri, M. Abubacker","doi":"10.2174/1876820201003010023","DOIUrl":null,"url":null,"abstract":"Introduction: In the management of patients with metastatic colorectal cancer (mCRC) failing anti-cancer agents/regimens are substituted by others. There is no data in the literature showing that combining 2 failing agents/regimens can induce tumor response. Case: We report a case with mCRC who failed first line XELOX/bevacicumab and second line FOLFIRI. However, the tumour responded to third line FOLFIRI/bevacizumab. Conclusion: Retreatment with bevacizumab in combination with a failing chemotherapy regimen is a possible treatment option after exhaustion of all standard treatments. This approach seems to be effective in overcoming clinical tumor drug resistance to irinotecan based chemotherapy","PeriodicalId":331708,"journal":{"name":"The Open Colorectal Cancer Journal","volume":"54 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2010-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bevacizumab May Overcome Clinical Tumor Drug Resistance to IrinotecanBased Chemotherapy in Patients with Metastatic Colorectal Cancer:Case Report\",\"authors\":\"J. Zekri, M. Abubacker\",\"doi\":\"10.2174/1876820201003010023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: In the management of patients with metastatic colorectal cancer (mCRC) failing anti-cancer agents/regimens are substituted by others. There is no data in the literature showing that combining 2 failing agents/regimens can induce tumor response. Case: We report a case with mCRC who failed first line XELOX/bevacicumab and second line FOLFIRI. However, the tumour responded to third line FOLFIRI/bevacizumab. Conclusion: Retreatment with bevacizumab in combination with a failing chemotherapy regimen is a possible treatment option after exhaustion of all standard treatments. This approach seems to be effective in overcoming clinical tumor drug resistance to irinotecan based chemotherapy\",\"PeriodicalId\":331708,\"journal\":{\"name\":\"The Open Colorectal Cancer Journal\",\"volume\":\"54 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Open Colorectal Cancer Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1876820201003010023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open Colorectal Cancer Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876820201003010023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bevacizumab May Overcome Clinical Tumor Drug Resistance to IrinotecanBased Chemotherapy in Patients with Metastatic Colorectal Cancer:Case Report
Introduction: In the management of patients with metastatic colorectal cancer (mCRC) failing anti-cancer agents/regimens are substituted by others. There is no data in the literature showing that combining 2 failing agents/regimens can induce tumor response. Case: We report a case with mCRC who failed first line XELOX/bevacicumab and second line FOLFIRI. However, the tumour responded to third line FOLFIRI/bevacizumab. Conclusion: Retreatment with bevacizumab in combination with a failing chemotherapy regimen is a possible treatment option after exhaustion of all standard treatments. This approach seems to be effective in overcoming clinical tumor drug resistance to irinotecan based chemotherapy
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
